The work
Looking at what the blood was already carrying
In 2010 her company began research on a blood test for cancer. The technology it developed collects circulating tumor cells from a patient's blood. It also caught something the field had been discarding.
Circulating tumor cells, collected
The technology developed under her leadership in 2010 was aimed at collecting circulating tumor cells, or CTCs, from the blood of cancer patients. It worked.
And the cells nobody was counting
The same method also collected large tumor associated giant cells that the field had previously ignored. Creatv calls them Cancer Associated Macrophage-Like cells, or CAMLs.
Present in patients, absent in controls
They were found in thousands of cancer patient samples across many cancer types, and not in healthy controls. That contrast is what turns a curiosity into a signal a clinician can use.
What Creatv has previously demonstrated for CAMLs
- Predict a cancer's aggressiveness, and multi-organ metastasis
- Serve as a universal companion diagnostic using blood instead of tissue
- Predict treatment response within roughly thirty days of a new therapy, in any solid tumor type
- Detect minimal residual disease
- Detect recurrence
Stated by Creatv Bio, 31 July 2024, announcing that the CAML biomarker had been included in a pivotal Phase 3 trial in metastatic breast cancer.
